Hemophilia B Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036

Hemophilia B Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036 - DelveInsight https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/consulting The Hemophilia B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia B pipeline products will significantly revolutionize the Hemophilia B market dynamics.DelveInsight's "Hemophilia B Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.The Hemophilia B market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.To Know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia B Market InsightsSome of the key facts of the Hemophilia B Market Report:• The Hemophilia B market size was valued at approximately USD 3,500 million in 2025 and is projected to reach around USD 4,000 million by 2036, expanding at a CAGR of 8.4% during the 2026-2036 forecast period.• The total market size in the US for Hemophilia B was estimated to be approximately USD 2 billion in 2025, which is expected to grow during the forecast period (2026-2036).• In 2025, in the US, among all the therapies, recombinant FIX - Extended Half-Life (EHL) captured the highest market share.• In March 2026, The Barbara Ann Karmanos Cancer Institute became the first and only independent cancer center in the United States to offer a newly approved hemophilia therapy. Etranacogene dezaparvovec-drlb, marketed as Hemegenix®, is a one-time gene therapy authorized by the U.S. Food and Drug Administration (FDA) for adults with hemophilia B. Steve W., a resident of Clinton Township, became the first patient to receive this treatment at the Karmanos Cancer Center in Detroit on October 28, 2025. Across the U.S., he is the 52nd individual to undergo this therapy following its clinical trials.• In March 2026, A single-dose gene therapy has demonstrated encouraging safety, effectiveness, and patient-reported outcomes in Hemophilia B. According to a recent study, a one-time infusion of fidanacogene elaparvovec sustained factor IX activity and enhanced patient-reported outcomes, while maintaining a favorable safety profile for up to six years in adult patients with Hemophilia B.• In February 2026, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to its supplemental Biologics License Application (sBLA) for HYMPAVZI. The application seeks to broaden the drug's approved use to include patients aged 6 years and older with hemophilia A or B who have inhibitors, as well as pediatric patients aged 6 to 11 years with hemophilia A or B without inhibitors. Currently in the United States, HYMPAVZI is approved for patients aged 12 years and older with hemophilia A without factor VIII (FVIII) inhibitors or hemophilia B without factor IX (FIX) inhibitors.• In January 2026, At the 67th American Society of Hematology (ASH) Annual Meeting and Exposition held in Florida, end-of-study results from the pivotal Phase 3 HOPE-B clinical trial (NCT03569891) were presented. These data underpinned the FDA's 2022 approval of CSL Behring and uniQure's etranacogene dezaparvovec, marketed as Hemgenix, an AAV vector-based gene therapy approved for the treatment of hemophilia B.• In September 2025, Pfizer announced a long-term safety and efficacy follow-up for Hemophilia B patients previously enrolled in the C0371005 (formerly SPK-9001-101) trial. Additionally, the company is launching a dose-escalation sub-study to assess the safety, tolerability, and kinetics of a higher dose, along with extended safety and efficacy monitoring. Importantly, participation in the original C0371005 trial is not a requirement for this sub-study.• In August 2025, Concizumab-mtci (Alhemo®) has been approved by the US FDA as the first once-daily subcutaneous prophylactic therapy for patients aged 12 and above with hemophilia A or B without inhibitors, broadening its use beyond those previously limited to inhibitor cases.• In July 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Alhemo® (concizumab-mtci) injection as a once-daily prophylactic therapy to prevent or reduce bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B (HA/HB) without inhibitors. This decision expands on the December 2024 approval for patients with HA/HB with inhibitors. Currently, many therapies for HA/HB without inhibitors require intravenous administration; with this approval, Alhemo® provides a subcutaneous treatment alternative for this patient population.• In April 2025, The FDA approved Qfitlia (fitusiran) for routine prophylaxis to help prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, regardless of the presence of factor VIII or IX inhibitors.• According to DelveInsight's estimates, the total prevalent cases of Hemophilia B in the 7MM were approximately 11,500 in 2025.• Among EU4 and the UK, France had highest diagnosed prevalent cases of Hemophilia B with approximately ~1,700 cases, followed by the UK and Italy. On the other hand, Spain had the lowest diagnosed prevalent cases of Hemophilia B, in 2025.• Among the Hemophilia B patients, i.e., with or without/ Non-Inhibitors, the latter one accounts for a higher number of Hemophilia B cases. In the US, around ~250 cases accounts for inhibitor and around ~4,500 cases for non-inhibitor in 2025.• In 2025, there were around ~1,600, ~1,700, and ~1,100 cases of mild, moderate and severe cases of Hemophilia B respectively in the US.• Key Hemophilia B Companies: CSL Behring/uniQure, Be Biopharma, Equilibra Bioscience, Sanofi, Novo Nordisk, Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others• Key Hemophilia B Therapies: HEMGENIX (etranacogene dezaparvovec-drlb), BE-101, SR604, Fitusiran (QFITLIA), Concizumab (ALHEMO), BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others• The lowest prevalent population of Hemophilia B were recorded in SpainHemophilia B OverviewHemophilia B is a rare genetic bleeding disorder caused by a deficiency or dysfunction of clotting factor IX, a protein essential for blood clotting. It is an inherited condition, typically passed down through the X chromosome, affecting mostly males, while females are usually carriers. Individuals with Hemophilia B experience prolonged bleeding after injuries, surgeries, or spontaneously in severe cases. Common symptoms include frequent bruising, joint bleeds, and internal bleeding. Treatment involves replacing the missing factor IX through regular infusions or advanced gene therapies. Early diagnosis and proper management are crucial to improving quality of life and preventing complications.Get a Free sample for the Hemophilia B Market Report:Hemophilia B EpidemiologyThe epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.Hemophilia B Epidemiology Segmentation:The Hemophilia B market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:• Total Diagnosed Prevalent Cases of Hemophilia B• Severity-specific Diagnosed Prevalent Cases of Hemophilia B• Age-specific Diagnosed Prevalent Cases of Hemophilia B• Diagnosed Prevalent Cases of Hemophilia B with or without Inhibitors• Treated Patient Pool of Hemophilia BDownload the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiological InsightsHemophilia B Drugs Uptake and Pipeline Development ActivitiesThe drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.Hemophilia B Therapies and Key Companies• HEMGENIX (etranacogene dezaparvovec-drlb): CSL Behring/uniQure• BE-101: Be Biopharma• SR604: Equilibra Bioscience• Fitusiran (QFITLIA): Sanofi• Concizumab (ALHEMO): Novo Nordisk• BBM-H901: Belief Biomed• ISU304: ISU ABXIS• TU7710: TiumBio• BE-101: Be Biopharma• REGV131: Regeneron Pharmaceuticals• PF-06838435: Pfizer• ANB-002: Biocad• AAV5-hFIXco-Padua: CSL Behring• VGB-R04: Shanghai Vitalgen BioPharma• AskBio009: Baxalta• AMA005: Amarna therapeutics• CB 2679d-GT: Catalyst Biosciences• FLT180a: Freeline Therapeutics• BBM-H901: Belief BioMed• SerpinPC: Centessa Pharmaceuticals• Concizumab: Novo Nordisk• Fitusiran: Sanofi• PF-06741086: PfizerTo know more about Hemophilia B treatment, visit @ Hemophilia B MedicationsHemophilia B Market Drivers• Advancements in factor IX replacement therapies: The availability of recombinant and extended half-life (EHL) factor IX therapies is improving bleeding control and reducing treatment burden.• Growing focus on prophylactic treatment: Increased adoption of preventive therapy to reduce spontaneous bleeding episodes and long-term joint complications is supporting market growth.• Emergence of gene therapies: One-time gene therapies have the potential to enable sustained production of factor IX and reduce dependence on frequent factor replacement therapy, creating significant market opportunities.• Robust pipeline of innovative therapies: Ongoing development of gene therapies, cell-based therapies, RNA-based approaches, and other novel treatment modalities is expected to expand treatment options.• Increasing awareness and improved diagnosis: Greater disease awareness, genetic testing, and improved access to specialized hemophilia treatment centers can contribute to earlier diagnosis and treatment.Hemophilia B Market Barriers• High treatment costs: Advanced therapies, particularly gene therapies, can involve substantial upfront costs, creating affordability and reimbursement challenges.• Limited patient population: As a rare disease, Hemophilia B has a relatively small patient pool, which can limit commercial opportunities and make clinical development challenging.• Uncertainty surrounding gene therapy durability and long-term safety: Variability in treatment response, potential loss of factor expression, immune-related complications, and limited long-term data may restrict broader adoption.• Complex eligibility requirements for gene therapy: Factors such as pre-existing antibodies, liver health, age restrictions, and the need for long-term monitoring can limit the number of eligible patients.• Reimbursement and market-access challenges: Payers may require strong evidence of long-term efficacy and cost-effectiveness before providing coverage for high-cost innovative therapies.• Limited healthcare infrastructure in developing regions: Inadequate access to diagnostic facilities, specialized treatment centers, and advanced therapies can restrict market penetration.Scope of the Hemophilia B Market Report• Study Period: 2022-2036• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]• Key Hemophilia B Companies: CSL Behring/uniQure, Be Biopharma, Equilibra Bioscience, Sanofi, Novo Nordisk, Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others• Key Hemophilia B Therapies: HEMGENIX (etranacogene dezaparvovec-drlb), BE-101, SR604, Fitusiran (QFITLIA), Concizumab (ALHEMO), BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others• Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies• Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies• Hemophilia B Unmet Needs, KOL's views, Analyst's views, Hemophilia B Market Access and ReimbursementMedia ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: info@delveinsight.comCity: AlbanyState: New YorkCountry: United StatesWebsite:About DelveInsightDelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.